A clinical trial led by local medical experts for patients with ovarian cancer relapse on a new medication has proven effective, according to experts from the Shanghai Cancer Center. The average survival rate for patients with the new medication is three times that of patients not receiving the therapy. Dr Wu Xiaohua, a leading expert, shared the study with medical professionals through the online meeting of the 2020 Congress of European Society for Medical Oncology.